2026年,Genflow Biosciences获得赠款批准,并计划推进基因疗法和再生医学。 Genflow Biosciences received approval for a grant and plans to advance gene therapy and regenerative medicine in 2026.

Gentflow Biosciences PLC宣布对一笔赠款进行行政批准,并概述了其2026年的优先事项,重点是促进生物技术研究与开发。 Genflow Biosciences PLC announced administrative approval of a grant and outlined its 2026 priorities, focusing on advancing biotechnology research and development. 该公司强调基因疗法和再生医学的进展,并计划扩大临床试验和加强伙伴关系。 The company emphasized progress in gene therapy and regenerative medicine, with plans to expand clinical trials and strengthen partnerships. 没有披露具体的资金数额或项目时间表。 No specific funding amounts or project timelines were disclosed.